LANTERN PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.18 USD | -1.44% |
|
-1.59% | +44.39% |
| 05-24 | Lantern Pharma Files $150 Million Mixed Shelf | MT |
| 05-09 | Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024 |
Presenter SpeechNicole Leber (Executives)Good afternoon, everyone. I am Nicole Leber with Inve...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Calendar
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.18
USD
Average target price
22
USD
Spread / Average Target
+255.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.39% | 66.49M | |
| +54.05% | 58.71B | |
| -2.02% | 41.31B | |
| +40.01% | 39.2B | |
| -10.22% | 27.4B | |
| +13.42% | 26.55B | |
| -21.60% | 18.98B | |
| +2.89% | 12.51B | |
| +22.40% | 11.94B | |
| +27.49% | 12.08B |
- Stock Market
- Equities
- LTRN Stock
- News Lantern Pharma Inc.
- Transcript : Lantern Pharma Inc., Q3 2022 Earnings Call, Nov 07, 2022
